{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000257","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.672837+00:00","generated_at":"2026-06-05T18:29:55.544865+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunic reports FY2023 net loss of $93.6M; raises $80M in Jan 2024 private placement","bullets":["Net loss for FY2023: $93.6M ($2.11 per share) vs $120.4M ($3.78 per share) in FY2022.","Cash as of Dec 31, 2023: $46.7M; extended to Q3 2025 after $80M Jan 2024 private placement tranche.","Positive interim phase 2 CALLIPER data: vidofludimus calcium reduced NfL in PMS; top-line data expected April 2025.","Phase 3 ENSURE interim futility analysis expected late 2024; first read-out Q2 2026.","New US patents granted for vidofludimus calcium dosing regimens, providing protection into 2041."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000257","json":"https://secwatch.observer/filing/0001193805-24-000257.json","markdown":"https://secwatch.observer/filing/0001193805-24-000257.md","text":"https://secwatch.observer/filing/0001193805-24-000257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000257/0001193805-24-000257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000257/e619294_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:29:55.544865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3071129e63693a724f0c6b944a89993c29f260d5","claim":"IMMUNIC, INC. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000257/0001193805-24-000257-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}